Tuesday, Moderna Inc MRNA stock is trading higher with a session volume of 8.0 million as per data from Benzinga Pro.On Friday, Moderna announced ongoing support from the U.S. Department of Health and Human Services (HHS) to accelerate the development of mRNA-based pandemic influenza vaccines.The award was made through the Rapid Response Partnership Vehicle (RRPV) Consortium with funding from the Biomedical Advanced Research and Development Authority (BARDA), part of the HHS Administration for Strategic Pre ...

Moderna's Vaccine Development - Moderna received a $590 million grant from the U S Department of Health and Human Services to accelerate the development of mRNA-based pandemic influenza vaccines, including mRNA-1018 [1][5] - The company initiated Phase 1/2 testing of mRNA-1018 in 2023, targeting healthy adults aged 18 and above, with positive preliminary results leading to the launch of a Phase 3 study [2][5] Bird Flu Impact and Market Response - The Centers for Disease Control and Prevention (CDC) reported widespread bird flu in wild birds and outbreaks in poultry and U S dairy cows, with several human cases among dairy and poultry workers [3] - Cal-Maine Foods, the largest U S egg producer, noted rising egg prices due to production limits caused by the bird flu outbreak [4] - Despite a 5% increase in Moderna's stock price, shares remain nearly 65% lower over the past year due to declining COVID-19 vaccine sales [4]

Moderna Inc (NASDAQ:MRNA) stock is surging today, up 8.7% at $37.02 at last glance, after the vaccine maker was awarded $590 million from the U.S. Health and Human Services Department to speed up the development of its bird flu vaccine, as the virus spreads rapidly throughout the country. MRNA has had a rough go of it since its meteoric rise at the height of Covid-19, as the demand vaccines waned. Just last week, the stock plummeted to its lowest levels since 2020 after a slashed forecast. Since last Januar ...

As Moderna (MRNA 6.75%) looks to shore up its business in the wake of its declining coronavirus vaccine sales, it's natural for investors to wonder about where the biotech will go in the near future.By early 2028, Moderna will be firmly within its next phase of life, potentially operating more like a traditional pharmaceutical business than like an up-and-coming biotech with a lot to prove about the value of its platform and its general competency in drug development.The question is, will that phase be bett ...

Funding and Development - Moderna received $590 million from the U.S. government through BARDA to accelerate the development of an mRNA-based vaccine targeting the H5N1 virus (bird flu) [1] - The funding will support the late-stage development of mRNA-1018, Moderna's investigational pandemic influenza vaccine against H5 and H7 avian influenza viruses [2] - The funds will also help expand clinical studies for up to five additional pandemic influenza subtypes [2] - This is the second time in less than a year that Moderna has secured U.S. government funding for its bird flu vaccine, following a $176 million award in July [4] Clinical Progress - Moderna initiated a phase I/II study for mRNA-1018 in 2023 in healthy adults [3] - Positive preliminary data from the phase I/II study has prompted the company to advance the vaccine to late-stage development [3] - Moderna plans to share data from the phase I/II study at a future medical meeting [3] Market and Industry Context - The U.S. CDC confirmed the first human death from the H5N1 virus earlier this month, with 67 human cases reported since the beginning of last year [5] - mRNA-based vaccines offer faster development and manufacturing scalability compared to traditional vaccines, a key advantage highlighted by BARDA [7] - Moderna's stock rose nearly 5% in after-market trading following the funding announcement, despite a 66% decline over the past year [6][7] Competitive Landscape - Moderna is not the only company working with BARDA on bird flu vaccines; CSL Seqirus has a deal for 150 million doses of its protein-based H5N1 vaccine and received a $34 million award in October [9] - CureVac is developing an mRNA-based bird flu vaccine in collaboration with GSK, currently in phase I/II studies [10] - Novavax is also developing a bird flu vaccine using a new approach, currently in preclinical studies [10]

On Monday, Moderna (MRNA) provided an update on its financial outlook and pipeline progress at the J.P. Morgan Healthcare Conference. At the conference, the company lowered its previously issued sales outlook for 2024 and 2025.Moderna reported unaudited/preliminary product sales between $3 billion and $3.1 billion for 2024, toward the lower end of its previously issued guidance of $3.0-$3.5 billion. MRNA also reduced its previously announced sales guidance for 2025 by $1 billion and now expects total revenu ...

Although the stock market was having a generally strong week, that isn't the case for vaccine technology company Moderna (MRNA -2.30%). The company, which was a leader in developing one of the initial COVID-19 vaccines, has plunged by 20% for the week as of mid-day Thursday.Disappointing sales guidance is the key reason for the plungeThe main reason for this week's decline is that Moderna lowered its 2025 full-year revenue guidance, and by a wide margin. The prior forecast called for $2.5 billion to $3.5 bi ...

Moderna (MRNA 0.90%) was one of the hottest companies of early pandemic times, delivering a coronavirus vaccine to market in record time and quickly generating blockbuster revenue from it. This helped the stock to skyrocket, reaching a high of more than $480 at its peak in 2021.Since then, though, Moderna has traveled along a rough path. Demand for the coronavirus vaccine has dropped significantly, and even the company's second approved product -- respiratory syncytial virus (RSV) vaccine mRESVIA -- hasn't ...

Moderna (MRNA 0.90%) shareholders have been having a rough time lately. The biotech stock rocketed higher last spring, but the gains didn't last long.Since reaching a peak last May, Moderna stock has tumbled by about 79%, and investors are starting to wonder if it could be a bargain now.Here's a look at what's been pressuring the formerly high-flying biotech stock to see if it can bounce back from the severe beating it's received over the past several months.Why Moderna Stock is getting hammeredOn Jan. 13, ...

A bad seven-month stretch just got worse for Moderna (MRNA -1.96%). The messenger RNA (mRNA) pioneer provided a business and pipeline update at the J.P. Morgan Healthcare Conference on Monday. This update wasn't well-received by investors, and Moderna's share price sank nearly 17%.The conventional investing wisdom is that you shouldn't "try to catch a falling knife." Moderna's stock chart certainly looks like a falling knife. Even before the latest decline, the biotech stock was down roughly 73% since early ...